Credentials
Positions
- Professor, Department of Pathology at NYU Grossman School of Medicine
- Professor, Department of Psychiatry at NYU Grossman School of Medicine
- Fellowship Program Director, Geriatric Psychiatry
Board Certifications
- American Board of Psychiatry & Neurology - Psychiatry, 1982
Education and Training
- Fellowship, Wayne State University Medical Center, Geriatric Psychiatry, 1982
- Residency, Metropolitan Hospital, 1980
- MD from SUNY-Downstate, 1976
Is this your profile?
Edit profileInsurance Plans Accepted
Please call the office for information about accepted insurance plans.
Nunzio Pomara, MD does not accept insurance.
Research My Research
Interests
pharmacogenetics, Alzheimer's disease, drug-induced cognitive toxicity, late-life depression
Research Summary
A major focus of Dr. Pomara’s research has been to elucidate pharmacokinetic and pharmacodynamic factors that may contribute to individual vulnerability to drug induced cognitive and psychomotor toxicity in the elderly. He has shown that certain variants of the APOE and TOMM40 genes increase risk for drug-induced adverse events unrelated to pharmacokinetic factors and likely reflecting pharmacodynamic mechanisms.
Other important contributions include his early reports of increased activity in the HPA axis associated with both aging and Alzheimer’s disease (AD), as determined by studies of baseline cortisol and dexamethasone response. These results led to the first pilot clinical trial that examined the cognitive effects of the glucocorticoid receptor antagonist, RU486, in AD. Dr. Pomara also provided early evidence of a decreased cortisol response to naltrexone and an elevation in CSF-glutamate in Alzheimer’s patients.
Dr. Pomara additionally presented the first evidence that late life depression, a condition associated with increased risk for AD or prodromal phase, may be accompanied by state-dependent disturbances in central and peripheral metabolism of amyloid-beta, a peptide implicated in AD.
Academic Contact
Academic office
145 East 32nd Street
Fifth Floor, 503
New York, NY 10016
Phone
Research Interests Timeline
Clinical Trials and Research Studies
-
The study will use a randomized 8-week double-blind placebo controlled parallel trial using escitalopram to test the associations between depressive symptoms (captured by the MADRS and other depression scales) and AD biomarkers in both CSF and plasma as
-
This multi-site study will be the first to evaluate the dose-dependent effects of t-PBM in amnestic Mild Cognitive Impairment (aMCI) and early Alzheimer s Disease (AD) (CDR of 0.5-1 FAST 1-4; age 65-85) in a randomized clinical trial of 8 weeks of t-PBM
Publications
-
Jacobs, Tovia; Jacobson, Sean R.; Fortea, Juan; Berger, Jeffrey S.; Vedvyas, Alok; Marsh, Karyn; He, Tianshe; Gutierrez-Jimenez, Eugenio; Fillmore, Nathanael R.; Gonzalez, Moses; Figueredo, Luisa; Gaggi, Naomi L.; Plaska, Chelsea Reichert; Pomara, Nunzio; Blessing, Esther; Betensky, Rebecca; Rusinek, Henry; Zetterberg, Henrik; Blennow, Kaj; Glodzik, Lidia; Wisniweski, Thomas M.; de Leon, Mony J.; Osorio, Ricardo S.; Ramos-Cejudo, Jaime
Immunity & ageing : I & A. 2024 Dec 01; 21(1):?-?
-
Ramos-Cejudo, Jaime; Corrigan, June K; Zheng, Chunlei; Swinnerton, Kaitlin N; Jacobson, Sean R; La, Jennifer; Betensky, Rebecca A; Osorio, Ricardo S; Madanes, Sharon; Pomara, Nunzio; Iosifescu, Dan; Brophy, Mary; Do, Nhan V; Fillmore, Nathanael R
Alzheimer's & dementia. 2024 Jun ; 20(6):4106-4114
-
Reichert Plaska, Chelsea; Heslegrave, Amanda; Bruno, Davide; Ramos-Cejudo, Jaime; Han Lee, Sang; Osorio, Ricardo; Imbimbo, Bruno P; Zetterberg, Henrik; Blennow, Kaj; Pomara, Nunzio
Brain, behavior & immunity. 2024 May 23;